Document is current
Any future updates will be listed below
-
Authors
Bourgeois, Benjamin
Spreitzer, Emil
Platero-Rochart, Daniel
Paar, Margret
Zhou, Qishun
Usluer, Sinem
de Keizer, Peter L. J. https://orcid.org/0000-0002-6948-925X
Burgering, Boudewijn M. T. https://orcid.org/0000-0002-4044-9596
Sánchez-Murcia, Pedro A. https://orcid.org/0000-0001-8415-870X
Madl, Tobias https://orcid.org/0000-0002-9725-5231
-
Funding
Funding for this research was provided by:
Austrian Science Fund (https://doi.org/10.55776/COE14)
Austrian Science Fund (https://doi.org/10.55776/P28854)
Austrian Science Fund (https://doi.org/10.55776/I3792)
Austrian Science Fund (https://doi.org/10.55776/DOC130)
Austrian Science Fund (https://doi.org/10.55776/W1226)
Österreichische Forschungsförderungsgesellschaft (864690)
Österreichische Forschungsförderungsgesellschaft (870454)
Österreichische Forschungsförderungsgesellschaft (912192)
- License Information
-
More Information
Article History
Received: 22 April 2024
Accepted: 5 June 2025
First Online: 1 July 2025
Competing interests
: We disclose the following potential conflicts of interest regarding the publication of this manuscript: This research was partly funded by Cleara Biotech. P.D.K. and T.M. hold shares in Cleara Biotech. B.B., E.S., P.D.K., and T.M. hold a published patent (WO/2021/165538) that describes compounds, wherein said compounds bind to p53 or preferably bind to p53 and inhibit the interaction of F0X04 with p53 in a cell. The binding and structural studies of FOXO4-DRI with p53 which are reported in this manuscript are related to the patent. P.D.K. and T.M. hold a published patent (WO/2023/180570) that covers the in vitro method for identifying anti-senescence compounds based on detecting the binding of said compound in the presence of at least one phosphorylated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The remaining authors declare no competing interests.
